Polymyositis
New polymyositis research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), real-world studies clarified remission and relapse patterns (including anti-ARS-linked relapse risk) and sharpened lung risk tracking, including high-risk signals during acute ILD hospitalizations. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Remission and relapse. Course-over-time data emerged, linking antibodies and relapse risk.
- Rituximab response signals. A mechanistic blood signal was tied to later rituximab response.
- Acthar in routine care. Routine-care reporting highlighted day-to-day outcomes after Acthar.
- Tracking lung risk. Risk stratification expanded from models to acute-hospital predictors.
- Complications and comorbidities. Multiple datasets quantified non-muscle burdens and linked them to outcomes.
New
September 2026
- CD4 count risk. Lower CD4 counts were linked to higher in-hospital death risk.
- Anti-MDA5 risk. Anti-MDA5 antibodies were linked to higher in-hospital death risk.
- Uneven muscle testing. MRI, EMG, or biopsy were not done for everyone.
- Thyroid disorders. Thyroid disorders were common and linked to swallowing problems.
August 2026
- Remission and relapse. Complete remission was linked to fewer relapses in one cohort.
- Anti-ARS and relapse. Anti-ARS antibodies were linked to a higher relapse risk.
- Rituximab blood changes. Early drops in some B cells matched later improvement.
- Diagnosis changes. Antibody tests plus biopsy often changed older polymyositis labels.
July 2026
- Cancer risk patterns. Cancers were seen mainly in higher-risk myositis groups.
- CT lung measures. Computer-read CT scores matched breathing tests and survival.
- Fibromyalgia symptoms. Fibromyalgia-like symptoms were common and linked to worse function.
- Early genetic signals. Genetic findings were early leads, not routine patient tests.
June 2026
- Acthar use. In routine care, doctors often noted overall health improved.
- Daily symptom goals. Reports focused on less pain and fewer limits in function.
- Antibody test differences. Antibody results changed by test brand and lab cutoff rules.
- Complex health overlap. Some reports involved lung disease, malnutrition, or other autoimmune overlap.
May 2026
- Infection risk patterns. Across inflammatory myositis studies, infections were reported fairly often, with higher rates in some immune-feature subgroups.
- Second cancers after a first cancer. Some large datasets followed people after a first cancer and reported that a second, separate cancer can occur later in a subset.
- Early lung vessel changes on CT. One CT imaging study in polymyositis reported lung blood-vessel differences that appeared before clear interstitial lung disease (scarring) was diagnosed.
- Treatment variation in clinics. Real-world reports described wide variation in immune-targeting medicines used, typically in selected cases rather than uniformly.
April 2026
- Severe viral illness signals. Studies more clearly linked severe viral illness signals with polymyositis, but they did not show that infections directly cause polymyositis.
- Flu-related outcomes. In polymyositis/dermatomyositis groups, influenza was associated with higher rates of hospitalization and short-term death compared with matched controls.
- Swallowing difficulty patterns. Swallowing problems were reported more often alongside certain antibodies and blood test patterns.
- Lung disease subtypes. Blood tests and CT scan details helped distinguish different types of myositis-related lung disease.
March 2026
- Pregnancy risks. In studies of inflammatory myopathy, pregnancies were linked with higher odds of several complications than pregnancies without myositis.
- Malnutrition during hospitalization. Malnutrition noted during a hospital stay was linked with worse in-hospital outcomes in dermatomyositis or polymyositis.
- FVC drop and lung outcomes. In myositis-related interstitial lung disease, a meaningful drop in forced vital capacity (FVC) over about a year was linked with worse long-term survival.
- Sorting myositis types. Studies suggested that MRI, muscle biopsy, and antibody testing are often needed together to tell similar-looking myositis subtypes apart.
February 2026
- Swallowing tests. Specialized swallowing tests detected dysphagia more often than routine bedside checks, which matters because dysphagia has been linked to aspiration pneumonia.
- Wearable activity data. Wrist-worn devices produced consistent activity measurements over months, and higher activity tended to align with better function and symptom reports.
- Lung risk grouping. Combining imaging patterns with an antibody result separated interstitial lung disease into short-term worsening risk groups, and IL-38 levels tracked with inflammation, especially when lung involvement was present.
January 2026
- Pregnancy flare risk. Complications were reported when disease flared during pregnancy.
- Early lung marker. A 1-month blood marker differed by later lung control in one subtype.
- Normal CK result. A normal CK blood test did not rule out myositis.
- Muscle repair signal. Lower CTRP1 was linked to weaker muscle repair in early research.
Get the monthly update by email
Subscribe here to receive an email when a new monthly polymyositis update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).